What Treatment Options Are Available for Patients Diagnosed With Renal Medullary Carcinoma?
More Programs and Publications Featuring Dr. Pavlos Msaouel
In this program:
Dr. Pavlos Msaouel shares how patients can effectively self-advocate if diagnosed with renal medullary carcinoma (RMC). First, a patient must know that treatment for RMC differs from other kidney cancers, so it is necessary to seek experts familiar with the particulars of RMC. Second, patients should reach out to communities who participate in RMC clinical trials. The contributions from patients and patient advocates have been immeasurable to the research progress of RMC. From this progress, disease outcomes have improved gradually and steadily. The average survival rate has improved six times: from 3 months to 18 months.
Read Transcript
Interviewer:
Dr. Msaouel, what treatment options are available for renal medullary carcinoma patients?
Dr. Pavlos Msaouel:
No, that is a wonderful and very important question and it is important, why -- because actually the treatment of RMC is very different from the treatment that we use for other kidney cancers. So, a lot of the treatments that work for most other kidney cancers do not work at all for RMC and treatments that do not work for other kidney cancers, work for RMC. So, this is why it is so crucial if you are diagnosed with RMC that you get in touch with people who are experts on managing this disease and so that is one.
Two, thankfully and again this is thanks in large part to the patient communities, we have been able to open clinical trials right now in the U.S. at our center at MD Anderson for individuals with RMC and it's not just us, there are other centers as well and we have networks now of physicians and researchers who are dedicated to helping individuals with RMC. So, there are clinical trials, things are moving forward and we could not have done that without the help of patients and without the help of their family members. The patient advocates, their contribution is immeasurable. Without these clinical trials and without this research that is going on, on a daily basis as we speak we wouldn't be where we are right now and I can tell you that we are right now at a better place than we were before. And what do I mean? When RMC was first described in the mid 90's, the average survival from diagnosis was just three months. Currently a few years ago the average survival in large institutions that are dedicated to treating individuals with RMC was in the range of 18 months and that was a few years ago. I believe now that we are doing better than that. So, it is not a huge change as we would've wanted, but it is better and so, that is gradual progress and through this research we will keep moving forward.
In retaining editorial control, the information produced by Diverse Health Hub does not encapsulate the views of our sponsors, contributors, or collaborators.
Importantly, this information is not a substitute for, nor does it replace professional medical advice, diagnosis, or treatment. If you have any concerns or questions about your health, you should always consult with a healthcare professional. To learn more about privacy, read our Privacy Policy.
